-
APASL 2023 | Prof. Hu Jinhua: Liver Cell Regeneration and Its Application in Liver Failure Treatment
Editor’s Note: At the 32nd Asia-Pacific Association for the Study of the Liver (APASL) annual conference, Professor Hu Jin-Hua from the Department of Hepatology at the Fifth Medical Center of…
-
Professor Xiaojun Huang Awarded International Collaboration Award by IACH
Renowned hematologist Professor Xiaojun Huang has been honored with the International Collaboration Award by the International Academy for Clinical Hematology (IACH). Prof. Huang, a pioneer in the successful implementation of haploidentical transplantation, has significantly contributed to the field of clinical hematology and played a crucial role in promoting global collaboration. The award ceremony took place…
-
APASL 2023 | Prof. Ji Dong: Clinical Characteristics of Elderly Drug-Induced Liver Injury Combined with Autoimmune Phenomena
Editor’s Note: In recent years, with the increase in health awareness, the incidence of drug-induced liver injury (DILI) has been rising. Immune responses can trigger inflammation and necrosis, leading to…
-
APASL 2023 | Prof. Li Hai: Latest Advances in Prognostic Research for Acute-on-Chronic Liver Failure
Editor’s Note: Acute-on-Chronic Liver Failure (ACLF) is a clinical syndrome characterized by a rapid and severe deterioration in a short term, often accompanied by multi-organ failure and a high mortality…
-
APASL 2023 | Prof. George Lau: Seeking the “Cure” for Liver Disease – A Hepatologist’s Thirty-Year Journey of Exploration
Editor’s Note: The 32nd annual meeting of the Asia-Pacific Association for the Study of the Liver (APASL) was held at the Taipei International Convention Center in Taiwan, China, from February…
-
APASL 2023 | Prof. Ning Qin: Treatment of ACLF with Infection and Its Impact on Liver Transplantation
Editor’s Note: Acute-on-chronic liver failure (ACLF) refers to a syndrome where, on the basis of chronic liver disease, the patient experiences a rapid deterioration of liver function within a short…
-
ASCO China Voice | Breaking Survival Records: Avapritinib Combined with Azacitidine Achieves Median Overall Survival of 29.3 Months in Unfit AML!
From June 2nd to 6th, 2023, the American Society of Clinical Oncology (ASCO) Annual Meeting took place in a grand hybrid format in Chicago. ASCO Annual Meeting stands as one of the world’s largest, academically esteemed, and most authoritative international conferences in oncology. Encompassing cutting-edge advancements in all sub-specialties of oncology, the event attracts the…
-
Year-End Review | Professor Jianxiang Wang: Targeted New Drugs Lead the Wave of Advances in AML Treatment, Immunotherapy Also on the Rise!
Acute Myeloid Leukemia (AML) is a malignant clonal disease originating from hematopoietic stem cells. Affected myeloid cells (leukemic cells) undergo uncontrolled proliferation, differentiation disorders, and blocked apoptosis, accumulating in the bone marrow and other hematopoietic tissues. This inhibits normal hematopoietic function and infiltrates organs such as lymph nodes, liver, and spleen, leading to clinical features…
Connecting Medical Expertise through Media